Annexon, Inc. (ANNX) |
|
3.85 0 (0%)
|
03-31 16:00 |
|
Open: |
3.85 |
Pre. Close: |
3.85 |
|
High:
|
3.93 |
Low:
|
3.81 |
|
Volume:
|
182,392 |
Market Cap:
|
194(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:16:43 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 5.57 One year: 6.38 |
| Support: |
Support1: 3.64 Support2: 3.02 |
| Resistance: |
Resistance1: 4.77 Resistance2: 5.46 |
| Pivot: |
4.01  |
| Moving Average: |
MA(5): 3.88  MA(20): 4.18
MA(100): 5.5 MA(250): 4.88 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 18.6 %D(3): 17.8 |
| RSI: |
RSI(14): 31.2 |
| 52-week: |
High: 7.65 Low: 2.05 |
| Average Vol(K): |
3-Month: 527 (K) 10-Days: 524 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ANNX ] has closed above bottom band by 31.5%. Bollinger Bands are 45.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.09 - 4.11 |
4.11 - 4.12 |
|
Low:
|
3.71 - 3.73 |
3.73 - 3.74 |
|
Close:
|
3.82 - 3.85 |
3.85 - 3.88 |
|
Company Description |
|
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California. |
Headline News |
Tue, 28 Mar 2023
Annexon (ANNX) Investor Presentation - Slideshow (NASDAQ:ANNX) - Seeking Alpha
Sat, 25 Mar 2023
One Annexon, Inc. (NASDAQ:ANNX) insider upped their stake by 59% in the previous year - Yahoo Finance
Fri, 17 Mar 2023
Cantor Fitzgerald Brokers Boost Earnings Estimates for Annexon ... - MarketBeat
Mon, 13 Mar 2023
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Tue, 07 Mar 2023
Will Annexon Inc (ANNX) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Mon, 06 Mar 2023
Annexon Biosciences GAAP EPS of -$0.48 beats by $0.05 ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
50 (M) |
| Shares Float |
21 (M) |
|
% Held by Insiders
|
2.3 (%) |
|
% Held by Institutions
|
103.9 (%) |
|
Shares Short
|
1,680 (K) |
|
Shares Short P.Month
|
1,320 (K) |
Stock Financials |
|
EPS
|
-2.65 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.84 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-31.9 |
|
Return on Equity (ttm)
|
-61.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.85 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-116 (M) |
|
Levered Free Cash Flow
|
-77 (M) |
Stock Valuations |
|
PE Ratio
|
-1.46 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.79 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.68 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
